Editor's note - Page 9 of 21 - Express Pharma

After sartans and ranitidine, where will NDMA show up next?

Slaying GMP non-compliance woes

Heeding the clarion call for sustainability

Price caps are a band aid hiding larger issues

CDSCO is blowin’ in the wind

Big Pharma to get bigger, but what about patients?

Protect IP to grow GDP

Time for a policy push for pharma

Will NDA-2’s first budget be any different for the pharma sector?

A silver lining to withdrawal of GSP benefits?